Carriers for improved drug delivery

• US 9,884,124 B2
• Filed: 02/06/2016
• Issued: 02/06/2018
• Est. Priority Date: 05/17/2012
• Status: Active Grant

• Current Assignee: Extend Biosciences, Inc.
• Original Assignee: Extend Biosciences, Inc.
• Inventors: Soliman, Tarik, Hales, Laura M., Sard, Howard P., Amere, Mukkanti
• Primary Examiner(s): Alstrum Acevedo, James H
• Assistant Examiner(s): MARTINEZ, TARA L
• Application Number:
  US15/017,602
• Publication Number:
  US 20160144049A1
• Time in Patent Office: 731 Days
• Field of Search: None
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61K 47/551 one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/00 Drugs for disorders of the urinary system
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system

Abstract

The invention provides carriers that enhance the absorption, half-life or bioavailability of therapeutic compounds. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.

Claims

1. A method of treating a subject with a therapeutic peptide, comprising administering a carrier-drug conjugate comprising a targeting group comprising vitamin D that is not hydroxylated at the Carbon 1 position, wherein said targeting group is stably linked to said therapeutic peptide.

2. The method of claim 1, wherein said therapeutic peptide is a protein having ghrelin activity comprising an amino acid sequence with at least a 90% sequence identity to SEQ ID NO:

5.

3. The method of claim 1, wherein said carrier-drug conjugate further comprises a scaffold.

4. The method of claim 1, wherein said carrier-drug conjugate is in a pharmaceutically acceptable formulation.

5. The method of claim 1, wherein said carrier-drug conjugate is delivered to said subject by a transdermal, oral, parenteral, subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intralesional, intracranial injection, infusion, inhalation, ocular, topical, rectal, nasal, buccal, sublingual, vaginal, or implanted reservoir mode.

6. The method of claim 5, wherein said carrier-drug conjugate is delivered to said subject by an intravenous mode.

7. The method of claim 3, wherein said scaffold is poly(ethylene glycol).

8. The method of claim 1, wherein said subject is a vertebrate.

9. The method of claim 8, wherein said vertebrate is a mammal.

10. The method of claim 9, wherein said mammal is selected from the group consisting of a primate, mouse, hamster, guinea pig, and rat.

11. The method of claim 9, wherein said mammal is a human.

12. The method of claim 2, wherein said subject is a vertebrate.

13. The method of claim 12, wherein said vertebrate is a mammal.

14. The method of claim 13, wherein said mammal is selected from the group consisting of a primate, mouse, hamster, guinea pig, and rat.

15. The method of claim 13, wherein said mammal is a human.